Antibody response after intradermal administration of recombinant hepatitis B vaccine in children.
Intradermal vaccination with recombinant hepatitis B vaccine was performed in 33 children (mean age 3.3 years). A 2 micrograms dose was given at 0, 1 and 6 months and antibody responses were determined 20 months after the initial dose. In 32/33 children, serum antibodies to HBs were demonstrated, with a geometric mean level of 26.5 IU/l, and 24 children (73%) had anti-HBs levels greater than or equal to 10 IU/l. The results indicate that intradermal vaccination with recombinant hepatitis B vaccine may be an alternative for vaccination of small children.
Wiström
J
J
Department of Infectious Diseases, University Hospital Umeå, Sweden.
Gustafsson
A
A
D002656:Child Day Care Centers; D002675:Child, Preschool; D005260:Female; D006510:Hepatitis B Antibodies / Q000096:biosynthesis*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D017325:Hepatitis B Vaccines; D006801:Humans; D007223:Infant; D007271:Injections, Intradermal; D008297:Male; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage / Q000276:immunology*
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic; D014761:Viral Hepatitis Vaccines